Company news
Femasys Inc. news in 2025
Femasys Inc.'s news releases, calls and decks from 2025, newest first.
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device
December 18, 2025
Femasys Announces Third Quarter Financial Results for 2025
November 14, 2025
Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe
November 10, 2025
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
November 3, 2025
Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe
October 22, 2025
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
October 16, 2025
Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership
September 25, 2025
Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed
September 22, 2025
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
September 11, 2025
Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand
September 8, 2025
Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios
September 2, 2025
Femasys Announces Pricing of $8.0 Million Underwritten Public Offering
August 25, 2025
Femasys Announces FemSperm™ Kit to Activate Gynecologists and Advance FemaSeed® Fertility Platform
August 21, 2025
Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control
August 20, 2025
Femasys Announces Second Quarter Financial Results for 2025
August 8, 2025
Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion
August 6, 2025
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
July 1, 2025
Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control
June 25, 2025
Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth
June 17, 2025
Femasys Announces Partnership with Carolinas Fertility Institute, One of America’s Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations
June 11, 2025
Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million
May 30, 2025
Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
May 29, 2025
Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update
May 8, 2025
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
March 27, 2025
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
March 19, 2025
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
March 18, 2025
Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach
March 13, 2025
Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials
February 25, 2025
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
February 10, 2025
Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
February 3, 2025
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
January 29, 2025
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
January 15, 2025